Please assess the completion status of the following clinical trial:

Trial Title: Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed lung cancer, excluding small cell carcinoma~* Inoperable stage I (T1-2N0) and II (T1-2N1, T3N0) disease, or stage IIIA (T3N1 andT1-3N2M0) and IIIB (TxN3M0, T4NxM0) diseases according to the American Joint Committee of Cancer criteria 1998~* The primary tumor must be radiographically measurable.~* Age \> 18.~* Karnofsky performance status \> 70.~* FEV1 sufficient for patients to tolerate radiation therapy which is at the discretion of the radiation oncologist, usually \> 800 ml~* Labs: WBC \> 3000; platelet count \> 100,000; serum creatinine \< 1.5 mg/dl or creatinine clearance \>60 ml/min.~* Laboratory values must be obtained \< 3 weeks prior to registration.~* A signed informed consent.~* Patients who failed prior chemotherapy are eligible. Patients with prior radiotherapy to the chest region are eligible as long as the normal tissue tolerance is not violated by repeat radiotherapy.~Exclusion Criteria:~* Patients with medical contraindication to chemotherapy or radiotherapy.~* Patients with myocardial infarction within the preceding six months or symptomatic heart disease, including uncontrolled or unstable angina, uncontrolled congestive heart failure, and uncontrolled arrhythmia.~* Women who are pregnant.~* Patients with small cell carcinoma or mesothelioma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1st dose cohort 15mg/m2 taxol plus RT (Type: EXPERIMENTAL): 15 mg/m2 Paclitaxel On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.~On Monday, Tuesday, Wednesday, Thursday, Friday Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible
- 2nd dose cohort20 mg/m2 taxol plus daily RT (Type: EXPERIMENTAL): None
- 3rd Dose Cohort --25mg/m2 taxol plus RT (Type: EXPERIMENTAL): None
- Phase II Arm --20mg/m2 taxol plus RT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).